Wilson Disease-Pipeline Review, H2 2016

Wilson Disease-Pipeline Review, H2 2016


  • Products Id :- GMDHC8905IDB
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Wilson Disease-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilson Disease-Pipeline Review, H2 2016, provides an overview of the Wilson Disease (Genetic Disorders) pipeline landscape.

Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech, swallowing and muscle stiffness. Treatment includes chelators and Vitamin E supplements.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wilson Disease-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilson Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wilson Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Wilson Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Wilson Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Wilson Disease (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Wilson Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Wilson Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Wilson Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Wilson Disease (Genetic Disorders)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Wilson Disease (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Wilson Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Wilson Disease Overview 6

Therapeutics Development 7

Pipeline Products for Wilson Disease-Overview 7

Pipeline Products for Wilson Disease-Comparative Analysis 8

Wilson Disease-Therapeutics under Development by Companies 9

Wilson Disease-Therapeutics under Investigation by Universities/Institutes 10

Wilson Disease-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Wilson Disease-Products under Development by Companies 13

Wilson Disease-Products under Investigation by Universities/Institutes 14

Wilson Disease-Companies Involved in Therapeutics Development 15

Dimension Therapeutics Inc 15

GMP-Orphan SAS 16

Revive Therapeutics Ltd 17

Wilson Therapeutics AB 18

Wilson Disease-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 25

Drug Profiles 27

DTX-701-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Gene Therapy to Activate ATP7B for Wilson's Disease-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

REV-005-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

trientine tetrahydrochloride-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

WTX-101-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Wilson Disease-Dormant Projects 34

Wilson Disease-Discontinued Products 35

Wilson Disease-Product Development Milestones 36

Featured News & Press Releases 36

Dec 05, 2016: Kadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA 36

Dec 05, 2016: Wilson Therapeutics Announces That WTX101 Meets The Primary Endpoint In Phase 2 Study In Wilson Disease 36

Nov 11, 2016: Wilson Therapeutics Presents Updated Preliminary Clinical Data on WTX101 at the AASLD Liver Meeting 37

Jun 23, 2016: Wilson Therapeutics Presents Preliminary Clinical Data on Decuprate at the 20th International Congress of Parkinson's Disease and Movement Disorders 38

May 30, 2016: Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology 39

May 18, 2016: Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled 40

Apr 14, 2016: Wilson Therapeutics presents data on Decuprate (WTX101) from ongoing Phase 2 study at The International Liver Congress 2016 40

Apr 16, 2015: Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015 41

Nov 17, 2014: Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 42

Jan 13, 2014: Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease 42

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Figures

Number of Products under Development for Wilson Disease, H2 2016 7

Number of Products under Development for Wilson Disease-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

List of Tables

Number of Products under Development for Wilson Disease, H2 2016 7

Number of Products under Development for Wilson Disease-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Wilson Disease-Pipeline by Dimension Therapeutics Inc, H2 2016 15

Wilson Disease-Pipeline by GMP-Orphan SAS, H2 2016 16

Wilson Disease-Pipeline by Revive Therapeutics Ltd, H2 2016 17

Wilson Disease-Pipeline by Wilson Therapeutics AB, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Wilson Disease-Dormant Projects, H2 2016 34

Wilson Disease-Discontinued Products, H2 2016 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Dimension Therapeutics Inc, GMP-Orphan SAS, Revive Therapeutics Ltd, Wilson Therapeutics AB

Wilson Disease Therapeutic Products under Development, Key Players in Wilson Disease Therapeutics, Wilson Disease Pipeline Overview, Wilson Disease Pipeline, Wilson Disease Pipeline Assessment

select a license

Single User License
USD 2000 INR 129800
Site License
USD 4000 INR 259600
Corporate User License
USD 6000 INR 389400

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com